Sylvia McBrinn
Severs in the Board of Directors. Extensive experience from the pharmaceutical industry especially commercial stages including launching new products, also co-founder and serial entrepreneur including Alzheimer company ReNetX where she negotiated a deal with AstraZeneca/MedImmune, also part of the SpringBoard Accelerator Program supporting female entrepreneurs and supported Rebiotix through the negotiations and acquisition by Ferring in 2018, its lead product Rebyota was the first ever bacterial based product to reecieve a BLA, which happened in 2022.